Ansa Biotechnologies to Highlight Next-Generation DNA Synthesis Innovation with Industry-Exclusive On-Time Delivery Guarantee at SynBioBeta 2026
Ansa Biotechnologies, a biotechnology firm specializing in next-generation DNA synthesis solutions, has announced its participation and presentation lineup for the upcoming SynBioBeta 2026 conference, scheduled to take place from May 4–7 in San Jose. The annual gathering is widely regarded as one of the most influential events in the synthetic biology ecosystem, bringing together a global network of innovators, scientists, investors, and entrepreneurs who are actively shaping the future of biology and biotechnology.
At this year’s event, Ansa Biotechnologies will showcase its latest advancements in DNA synthesis technology and engage directly with attendees at booth 312. The company is positioning itself as a key enabler of cutting-edge research, offering high-quality synthetic DNA products designed to meet the growing demands of modern life sciences applications. Conference participants will have the opportunity to interact with Ansa’s leadership team, learn about the company’s proprietary platform, and hear firsthand experiences from customers who are leveraging its solutions in real-world research and development settings.
Central to Ansa’s value proposition is its ability to produce direct, sequence-perfect clonal DNA constructs across a wide range of lengths—from as short as 100 base pairs (bp) to as long as 50 kilobases (kb). This capability addresses a critical need in the industry, where researchers increasingly require longer and more complex DNA sequences to support advanced applications. Ansa emphasizes that its products combine high accuracy with rapid turnaround times, with some orders delivered in as little as 11 business days. In addition, the company highlights competitive pricing starting at $0.13 per base pair, along with what it describes as the industry’s only guarantee of complete and on-time order fulfillment.
These features are particularly relevant for scientists working in fields such as cell and gene therapy, genome engineering, vaccine development, bioproduction, and agrigenomics. As biological research becomes more sophisticated, the ability to design and assemble large, intricate DNA constructs is becoming increasingly important. Ansa’s platform aims to streamline this process, enabling researchers to bypass traditional bottlenecks associated with DNA assembly and accelerate the pace of discovery.
Jason T. Gammack, Chief Executive Officer of Ansa Biotechnologies, emphasized the importance of the SynBioBeta conference as a platform for collaboration and knowledge exchange within the synthetic biology community. He noted that the event provides an opportunity to connect with forward-thinking stakeholders who are driving innovation across multiple domains. According to Gammack, Ansa is committed to delivering DNA synthesis solutions that prioritize accuracy, reliability, and efficiency, without forcing researchers to compromise on sequence complexity or length.
Gammack also highlighted the company’s focus on customer experience, underscoring the importance of trust in scientific workflows. By featuring customer perspectives at the conference, Ansa aims to demonstrate the real-world impact of its technology and reinforce its commitment to meeting the evolving needs of the research community. The company believes that scientists should be able to rely on consistent quality and predictable delivery timelines as standard expectations, rather than trade-offs.
As part of its conference presence, Ansa Biotechnologies will participate in several high-profile presentations and panel discussions. Gammack himself will take the main stage on May 5 to deliver a presentation titled “Up and to the Right: A New Era of Innovation Enabled by AI and Complex DNA.” This session will explore how advances in artificial intelligence, combined with increasingly sophisticated DNA synthesis capabilities, are driving a new wave of innovation in biotechnology.
In addition, Gammack will join a breakout panel discussion titled “Breaking the Barriers of DNA Synthesis: Shattering the Ceiling,” where industry experts will examine the technical and commercial challenges associated with pushing the limits of DNA synthesis. These discussions are expected to provide valuable insights into how emerging technologies are overcoming longstanding constraints in the field.
Another notable session, “Skip the Assembly, Go Straight to Your Next Breakthrough: How Innovative DNA Synthesis Is Changing What’s Possible in Biopharma,” will feature participation from leaders across the biotechnology sector, including representatives from Gilead Sciences, Integrated DNA Technologies, and Hexagon Bio. Moderated by Ansa’s Geoff Hamilton, this panel will focus on how advances in DNA synthesis are enabling faster and more efficient drug development processes, particularly in the biopharmaceutical industry.
In parallel, Ansa’s Scott Fay will contribute to a discussion on biosecurity titled “The New Biosecurity Frontier: AI, Automation, and the Rise of Biodefense in Programmable Biology.” This session will address the growing importance of safeguarding biological technologies in an era of rapid innovation, highlighting the role of policy, technology, and industry collaboration in ensuring responsible use.
Beyond its technical capabilities, Ansa Biotechnologies also emphasizes its commitment to sustainability and biosecurity. The company’s DNA synthesis platform is designed to operate without the use of harsh chemicals, helping to preserve DNA integrity while reducing environmental impact. This approach aligns with broader industry efforts to adopt more sustainable practices in biotechnology manufacturing.
Furthermore, Ansa operates under a comprehensive biosecurity framework and adheres to guidelines established by the U.S. Office of Science and Technology Policy for nucleic acid synthesis screening. Compliance with these standards reflects the company’s dedication to maintaining high levels of safety and accountability in its operations, particularly as synthetic biology technologies become more powerful and accessible.
All of Ansa’s products are manufactured exclusively in the United States, ensuring quality control and supply chain reliability. The company’s platform is designed to integrate seamlessly into existing laboratory workflows, allowing researchers to adopt its solutions without significant disruption. By combining scalability, precision, and ease of use, Ansa aims to empower scientists to tackle increasingly complex biological challenges.
As the synthetic biology field continues to evolve, events like SynBioBeta play a crucial role in fostering collaboration and driving innovation. Ansa Biotechnologies’ participation underscores its position as a key contributor to this dynamic landscape. Through its presentations, partnerships, and product offerings, the company is working to redefine what is possible in DNA synthesis and to support the next generation of breakthroughs in biotechnology.
Ultimately, Ansa’s presence at SynBioBeta 2026 reflects its broader mission: to provide researchers with the tools they need to unlock the full potential of biology. By addressing critical challenges in DNA synthesis and enabling more ambitious scientific endeavors, the company is helping to accelerate progress across a wide range of applications, from healthcare to agriculture and beyond.
About Ansa Biotechnologies
Ansa Biotechnologies is redefining DNA synthesis with a bold commitment to quality, customer satisfaction, and success. The Ansa On-Time Guarantee is simple and clear: your complete order on time or it’s free. This unprecedented level of service reliability and predictability is made possible by Ansa’s dedicated team of experts and proprietary enzymatic synthesis platform, which can rapidly and accurately produce even the highly complex DNA elements that challenge legacy approaches.
Products are delivered as sequence-perfect clonal DNA or sequence-verified linear double-stranded DNA fragments. Headquartered in Emeryville, CA, Ansa is empowering a global community of scientists to accelerate breakthroughs in healthcare, life sciences, and other industries powered by synthetic DNA.
Source Link:https://www.businesswire.com/
